




# COVID-19 VACCINATION UPDATE

# Housekeeping Notes


- Please mute your microphones.
- This meeting will be recorded.
- Submit your questions via the chat feature.

# Vaccination Steering Committee






# Background




Average daily cases per 100,000 people in past week



Source: New York Times 12-6-2020

# Coronavirus in the U.S.


## New reported deaths by day



These are days with a data reporting anomaly. Read more [here](#).


## Cumulative Deaths – 281,202

## Hospitalized Covid-19 patients by day



# COVID-19 Cases in New Jersey

## NJ COVID-19 Dashboard



Data are provisional and subject to revision with further investigation.

NJDOH Dashboard

Camden County is among the leading areas statewide for new COVID-19 cases.

507 new cases occurred on Dec. 6 alone, bringing the reported total to 21,635 people since March.

NJDOH reports 700 total COVID-19 deaths in Camden County.



Pfizer & Moderna  
*A Closer Look*



# Many Vaccines are in Development.

The FDA is likely to grant “emergency use authorization.”

Virtua anticipates receiving a limited quantity in mid-December, with additional shipments arriving every week to follow.



# mRNA vaccines

- NOT new technology
- NOT live virus
- NOT affecting DNA



# Study Results: Pfizer

43,500+ study participants

Reported 95% efficacy at 7 days after second vaccination

- 170 cases of COVID-19 observed in trial
  - 162 infections among the placebo group
  - 8 infections among the group that received the two-dose vaccine
- 10 cases of severe COVID-19 infection among participants
  - 9 severe infections among the placebo group
  - 1 severe infection among the vaccine-treated group

This suggests the vaccine may prevent not only mild cases, but also the type of serious disease that leads patients to die or be hospitalized.

# Study Results: Moderna

30,000+ study participants

Reported 94.1% efficacy

- 196 cases of COVID-19 observed in trial
  - 185 infections among the placebo group
  - 11 infections among the vaccinated drug group
- 30 cases of severe COVID-19 infection among participants
  - All 30 severe infections were among the placebo group

No cases of severe disease occurred in the vaccinated group.

# Reactions / Undesirable Effects

Resolve within a few days

Pain at injection site

- Up to 80%, mild or moderate

“Common Reactions”

*At least 1 in 10*

- Fatigue
- Headache
- Myalgia/muscle aches
- Chills
- Fever

May be more prominent after second injection.

# Reactions / Undesirable Effects

## **Moderna Press Release**

Severe events that occurred in greater than 2% of patients included fatigue and muscle pain, which happened in nearly 1 patient in 10, and headache and achiness.

These events were “generally short-lived.”



# Top Questions

# Safety & Efficacy Questions

- Should people who had COVID-19 still get vaccinated?
- How long after receiving the vaccine can someone be considered immune, and how long does the immunity last?



# Distribution Questions

- Which departments and divisions will receive the vaccine first?
- How long will it take for all colleagues to be vaccinated?
- When will vaccines be available for our families?
- Is the vaccine mandatory for all colleagues?



Stay Connected

# Take the Survey on Virtua Works


The screenshot displays the Virtua Health dashboard interface. At the top left is the Virtua Health logo and a search bar. The main content area is divided into several sections:

- Welcome**: A header section with a settings gear icon.
- Announcements**: A section with a megaphone icon and "5 items". A red oval highlights an announcement titled "Urgent! Please Complete Vaccine Survey Today" with a COVID-19 vaccine icon. The text below the icon reads: "Please click link below to take a short survey to communicate your desire to receive the COVID-19 COVID-19".
- Applications**: A section with a puzzle piece icon and "11 items". It contains a grid of application icons: Favorites, Personal Information, Time Off, Pay, Expenses, Performance, Goals, Feedback, Career, Directory, and Additional Resources.
- Need Assistance with Virtua Works?**: A section with a Q&A icon and text: "Help text is located at the top of the screen for many functions. Guided tours are available and active".
- New Recognition Platform**: A section with the WE Applaud logo and text: "Have you checked out WE Applaud, Virtua's new online colleague appreciation and recognition platform?". A "View More" link is at the bottom.
- Inbox**: A section with an envelope icon and "0 items".

# Sign Up for MyChart



**MyChart**  
Personal Health Record



# Read All Email Communications

Dec. 1, 2020 Issue 73

## Coronavirus Update

Rising to the Challenge Together



### Questions about the Coronavirus Vaccine?

The federal government has been working since the pandemic started to get one or more COVID-19 vaccines available as soon as possible. There are several vaccines under investigation, and some of them have advanced to large-scale clinical trials.



## Clinician Update November 19, 2020

### Wave 2 COVID-19 Response

Virtua held a special webinar last night to help clinicians navigate the response to Wave 2. The discussion involved the sharing of latest numbers and trends; screening, treatment, and safety protocols; testing options; emotional support resources; and more. Over 300 clinicians attended.

Some of the highlights:

- Dr. Andy Cohen discussed trends...

# Consult the VINE Regularly

Visit the [Vaccination Information Hub](#) on the Virtua VINE.

Look for FAQs, fact sheets, videos, and operational updates in the days/weeks ahead.



# When Questions Arise:

- Consult the VINE.
- Check with your leader.
- Send your questions to [virtuainfo@virtua.org](mailto:virtuainfo@virtua.org).

Q&A